Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Sign Up to like & getrecommendations! Published in 2022 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s360574
Abstract: Abstract Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has… read more here.
Keywords: tepotinib capmatinib; met exon; lung cancer;